Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model

Toxicology and Applied Pharmacology

Volumn 266, Issue 1, 2013, Pages 109-121

  Desai, Varsha G ^a   Herman, Eugene H ^b   Moland, Carrie L ^a   Branham, William S ^a   Lewis, Sherry M ^a   Davis, Kelly J ^a   George, Nysia I ^a   Lee, Taewon ^c   Kerr, Susan ^d   Fuscoe, James C ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c Korea University   (South Korea)

^d ARKANSAS HEART HOSPITAL   (United States)

Author keywords

Cardiac lesions; Cardiac troponin T; Doxorubicin; Hematotoxicity; Male B6C3F1 mice

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; DOXORUBICIN; HEMOGLOBIN; SODIUM CHLORIDE; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOMYOPATHY; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROCARDIOGRAM; ERYTHROCYTE COUNT; FOOD INTAKE; HEART INJURY; HEART RATE; HEMATOCRIT; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MOUSE; NONHUMAN; ORGAN WEIGHT; TISSUE INJURY;

ANIMALS; BODY WEIGHT; CARDIOTOXINS; CHRONIC DISEASE; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HEART; HEART DISEASES; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; ORGAN SIZE; SPECIES SPECIFICITY;

MUS;

EID: 84870218977     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.10.025     Document Type: Article

References (94)

1. Ahmad S.S., Idris S.F., Follows G.A., Williams M.V. Primary testicular lymphoma. Clin. Oncol. 2012, 24:358-365.
2. Astra L.I., Hammond R., Tarakji K., Stephenson L.W. Doxorubicin-induced canine CHF: advantages and disadvantages. J. Card. Surg. 2003, 18:301-306.
3. Bardi E., Bobok I., Olah A.V., Kappelmayer J., Kiss C. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer. Pathol. Oncol. Res. 2007, 13:249-253.
4. Batty N., Hagemeister F.B., Feng L., Romaguera J.E., Rodriguez M.A., McLaughlin P., Samaniego F., Copeland A., Dabaja B.S., Younes A. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk. Lymphoma 2012, 53:801-806.
5. Bertazzoli C., Bellini O., Magrini U., Tosana M.G. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat. Rep. 1979, 63:1877-1883.
6. Berthiaume J.M., Wallace K.B. Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment. Cardiovasc. Toxicol. 2007, 7:178-191.
7. Bertinchant J.P., Polge A., Juan J.M., Oliva-Lauraire M.C., Giuliani I., Marty-Double C., Burdy J.Y., Fabbro-Peray P., Laprade M., Bali J.P., Granier C., De La Coussaye J.E., Dauzat M. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin. Chim. Acta 2003, 329:39-51.
8. Berul C.I., Aronovitz M.J., Wang P.J., Mendelsohn M.E. In vivo cardiac electrophysiology studies in the mouse. Circulation 1996, 94:2641-2648.
9. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 1978, 62:865-872.
10. Bjelogrlic S.K., Radic J., Radulovic S., Jokanovic M., Jovic V. Effects of dexrazoxane and amifostine on evolution of doxorubicin cardiomyopathy in vivo. Exp. Biol. Med. 2007, 232:1414-1424.
11. Blijham G.H. Prevention and treatment of organ toxicity during high-dose chemotherapy: an overview. Anticancer Drugs 1993, 4:527-533.
12. Boussios S., Pentheroudakis G., Katsanos K., Pavlidis N. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann. Gastroenterol. 2012, 25:106-118.
13. Burke B.E., Olson R.D., Cusack B.J., Gambliel H.A., Dillmann W.H. Anthracycline cardiotoxicity in transgenic mice overexpressing SR Ca2+ -ATPase. Biochem. Biophys. Res. Commun. 2003, 303:504-507.
14. Burtness B., Windsor S., Holston B., DiStasio S., Staugaard-Hahn C., Abrantes J., Kneuper-Hall R., Farber L., Orell J., Bober-Sorcinelli K., Haffty B.G., Reiss M. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. Cancer J. Sci. Am. 1999, 5:224-229.
15. Carr B.I. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004, 127:S218-S224.
16. Carvalho C., Santos R.X., Cardoso S., Correia S., Oliveira P.J., Santos M.S., Moreira P.I. Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem. 2009, 16:3267-3285.
17. Center for Drug Evaluation, Research (CDER) Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers http://www.fda.gov/cder/guidance/index.htm.
18. Cheng X., Xue W., Diao H., Xia S., Zuo L., He A., Gao F., Huang Z., Chen J., Zhang J. Antitumor activity and toxicological properties of doxorubicin conjugated to (alpha),(beta)-poly[(2-hydroxyethyl)-L-aspartamide] administered intraperitoneally in mice. Anticancer Drugs 2010, 21:362-371.
19. Collinson P.O., Boa F.G., Gaze D.C. Measurement of cardiac troponins. Ann. Clin. Biochem. 2001, 38:423-449.
20. Davis J., Maillet M., Miano J.M., Molkentin J.D. Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research. Circ. Res. 2012, 111:761-777.
21. Denine E.P., Schmidt L.H. Adriamycin induced myopathies in the rhesus monkey with emphasis on cardiomyopathy. Toxicol. Appl. Pharmacol. 1975, 33. (Abstract no.101).
22. Desai V.G., Fuscoe J.C. Transcriptional profiling for understanding the basis of mitochondrial involvement in disease and toxicity using the mitochondria-specific MitoChip. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2007, 616:210-212.
23. Desai V.G., Lee T., Delongchamp R.R., Moland C.L., Branham W.S., Fuscoe J.C., Leakey J.E.A. Development of mitochondria-specific mouse oligonucleotide microarray and validation of data by real-time PCR. Mitochondrion 2007, 7:322-329.
24. Desai V.G., Lee T., Delongchamp R.R., Leakey J.E.A., Lewis S.M., Lee F., Moland C.L., Branham W.S., Fuscoe J.C. Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver. Mitochondrion 2008, 8:181-195.
25. Doetschman T., Azhar M. Cardiac-specific inducible and conditional gene targeting in mice. Circ. Res. 2012, 110:1498-1512.
26. Doroshow J.H., Locker G.Y., Ifrim I., Myers C.E. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J. Clin. Invest. 1981, 68:1053-1064.
27. Fahim M.A., Kataya H., El-Kharrag R., Amer D.A., Al-Ramadi B., Karam S.M. Ghrelin attenuates gastrointestinal epithelial damage induced by doxorubicin. World J. Gastroenterol. 2011, 17:3836-3841.
28. Gadea E., Thivat E., Planchat E., Morio B., Durando X. Importance of metabolic changes induced by chemotherapy on prognosis of early-stage breast cancer patients: a review of potential mechanisms. Obes. Rev. 2012, 13:368-380.
29. Gralla E.J., Fleischman R.W., Luthra Y.K., Stadnicki S.W. The dosing schedule dependent toxicities of adriamycin in beagle dogs and rhesus monkey. Toxicology 1979, 13:263-273.
30. Herman E.H., Ferrans V.J. ICRF-187: reduction of chronic daunorubicin and doxorubicin cardiotoxicity in rabbits, beagle dogs and miniature pigs. Drugs Exp. Clin. Res. 1983, 9:483-490.
31. Herman E.H., Ferrans V.J. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin. Oncol. 1998, 25:15-21.
32. Herman E.H., Rahman A., Ferrans V.J. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 1983, 43:5427-5432.
33. Herman E.H., El-Hage A.N., Ferrans V.J., Ardalan B. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol. Appl. Pharmacol. 1985, 78:202-214.
34. Herman E.H., Lipshultz S.E., Rifai N., Zhang J., Papoian T., Yu Z.X., Takeda K., Ferrans V.J. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998, 58:195-197.
35. Herman E.H., Zhang J., Lipshultz S.E., Rifai N., Chadwick D., Takeda K., Yu Z.X., Ferrans V.J. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. 1999, 17:2237-2243.
36. Herman E.H., Zhang J., Chadwick D.P., Ferrans V.J. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. 2000, 45:329-334.
37. Herman E.H., Zhang J., Rifai N., Lipshultz S.E., Hasinoff B.B., Chadwick D.P., Knapton A., Chai J., Ferrans V.J. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicinand mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. 2001, 48:297-304.
38. Honda M., Miura A., Izumi Y., Kato T., Ryotokuji T., Monma K., Fujiwara J., Egashira H., Nemoto T. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Dis. Esophagus 2010, 23:641-645.
39. Iliskovic N., Singal P.K. Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am. J. Pathol. 1997, 150:727-734.
40. Jaenke R.S. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res. 1976, 36:2958-2966.
41. Jahnukainen K., Jahnukainen T., Salmi T.T., Svechniko K., Eksborg S., Soder O. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats. Cancer Res. 2001, 61:6423-6427.
42. Joseph A., Lee T., Moland C.L., Branham W.S., Fuscoe J.C., Leakey J.E.A., Allaben W.T., Lewis S.M., Ali A.A., Desai V.G. Effect of (+)-usnic acid on mitochondrial functions as measured by mitochondria-specific oligonucleotide microarray in liver of B6C3F1 mice. Mitochondrion 2009, 9:149-158.
43. Kjekshus J.K., Maroko P.R., Sobel B.E. Distribution of myocardial injury and its relation to epicardial ST segment changes after coronary artery occlusion in the dog. Cardiovasc. Res. 1972, 6:490-499.
44. Kralickova P., Melichar B., Malir F., Roubal T. Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy. J. Exp. Clin. Cancer Res. 2004, 23:579-584.
45. Kunitomo M., Yamaguchi Y., Matsushima K. Hyperlipidemic effects of adriamycin in rats. Jpn. J. Pharmacol. 1985, 39:323-329.
46. Lebrecht D., Setzer B., Ketelsen U.P., Haberstroh J., Walker U.A. Time-dependent and tissue-Specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003, 108:2423-2429.
47. Lee T., Manjanatha M.G., Aidoo A., Moland C.L., Branham W.S., Fuscoe J.C., Ali A.A., Desai V.G. Expression analysis of hepatic mitochondria-related genes in mice exposed to acrylamide and glycidamide. J. Toxicol. Environ. Health A 2012, 75:324-339.
48. Lipshultz S.E., Rifai N., Dalton V.M., Levy D.E., Silverman L.B., Lipsitz S.R., Colan S.D., Asselin B.L., Barr R.D., Clavell L.A., Hurwitz C.A., Moghrabi A., Samson Y., Schorin M.A., Gelber R.D., Sallan S.E. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. 2004, 351:145-153.
49. Lipshultz S.E., Franco V.I., Henkel J.M., Miller T.L. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol. Res. Pract. 2011, 1.
50. Lui R.C., Laregina M.C., Herbold D.R., Johnson F.E. Testicular cytotoxicity of intravenous doxorubicin in rats. J. Urol. 1986, 136:940-943.
51. Mackay B., Ewer M.S., Carrasco C.H., Benjamin R.S. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct. Pathol. 1994, 18:203-211.
52. Mair J. Progress in myocardial damage detection: new biochemical markers for clinicians. Crit. Rev. Clin. Lab. Sci. 1997, 34:1-66.
53. Masci G., Magagnoli M., Grimaldi A., Covini G., Carnaghi C., Rimassa L., Santoro A. Metastasis of hepatocellular carcinoma to the heart: a case report and review of the literature. Tumori 2004, 90:345-347.
54. Matsumura M., Nishioka K., Fujii T., Yoshibayashi M., Nozaki K., Nakata Y., Temma S., Ueda T., Mikawa H. Age-related acute adriamycin cardiotoxicity in mice. J. Mol. Cell. Cardiol. 1994, 26:899-905.
55. Mettler F.P., Young D.M., Ward J.M. Adriamycin induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 1977, 37. (I).
56. Mitchell G.F., Jeron A., Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am. J. Physiol. Heart Circ. Physiol. 1998, 274:H747-H751.
57. Molyneux G., Andrews M., Sones W., York M., Barnett A., Quirk E., Yeung W., Turton J. Haemotoxicity of busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a brief regimen of drug administration. Cell Biol. Toxicol. 2011, 27:13-40.
58. Olson L.E., Bedja D., Alvey S.J., Cardounel A.J., Gabrielson K.L., Reeves R.H. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase. Cancer Res. 2003, 63:6602-6606.
59. Panis C., Herrera A.C.S.A., Victorino V.J., Campos F.C., Freitas L.F., De Rossi T., Colado Simao A.N., Cecchini A.L., Cecchini R. Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res. Treat. 2012, 133:89-97.
60. Papadopoulou L.C., Theophilidis G., Thomopoulos G.N., Tsiftsoglou A.S. Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. Biochem. Pharmacol. 1999, 57:481-489.
61. Rosenoff S.H., Olson H.M., Young D. Adriamycin induced cardiac damage in the mouse: a small animal model of cardiotoxicity. J. Natl. Cancer Inst. 1975, 55:191-194.
62. Schimmel K.J.M., Richel D.J., van den Brink R.B.A., Guchelaar H.J. Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev. 2004, 30:181-191.
63. Sellers R.S., Morton D., Michael B., Roome N., Johnson J.K., Yano B.L., Perry R., Schafer K. Society of Toxicologic Pathology position paper: organ weight recommendations for toxicology studies. Toxicol. Pathol. 2007, 35:751-755.
64. Shuai Y., Guo J., Dong Y., Zhong W., Xiao P., Zhou T., Zhang L., Peng S. Global gene expression profiles of MT knockout and wild-type mice in the condition of doxorubicin-induced cardiomyopathy. Toxicol. Lett. 2011, 200:77-87.
65. Sieber S.M., Correa P., Young D.M. Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuamn primates. Pharmacology 1980, 20:9-14.
66. Singh M., Murriel C.L., Johnson L. Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res. 2012, 72:2695-2700.
67. Socolovsky M. Molecular insights into stress erythropoiesis. Curr. Opin. Hematol. 2007, 14:215-224.
68. Solcia E., Ballerini L., Bellini O. Cardiomyopathy of doxorubicin in experimental animals. Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori 1981, 67:461-472.
69. Song H., Li X., Zhu C., Wei M. Glomerulosclerosis in adriamycin-induced nephrosis is accelerated by a lipid-rich diet. Pediatr. Nephrol. 2000, 15:196-200.
70. Stavridi F., Palmieri C. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. Expert. Rev. Anticancer. Ther. 2008, 8:1859-1869.
71. Sun X., Zhou Z., Kang Y.J. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res. 2001, 61:3382-3387.
72. Tan G., Lou Z., Liao W., Zhu Z., Dong X., Zhang W., Li W., Chai Y. Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. PLoS One 2011, 6:e27683. 10.1371/journal.pone.0027683.
73. Tan L.B., Hothi S.S., Tan D.K.H. Troponin leak in heart failure: moving forward to arrest cardiomyocyte attrition and promote myocardial regeneration. Int. J. Cardiol. 2012, 10.1016/j.ijcard.2012.01.090.
74. Tepler I., Elias L., Smith J.W., Hussein M., Rosen G., Chang A.Y.-C., Moore J.O., Gordon M.S., Kuca B., Beach K.J., Loewy J.W., Garnick M.B., Kaye J.A. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996, 87:3607-3614.
75. Thompson K.L., Rosenzweig B.A., Zhang J., Knapton A.D., Honchel R., Lipshultz S.E., Retief J., Sistare F.D., Herman E.H. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother. Pharmacol. 2010, 66:303-314.
76. Tomlinson C.W., McGrath G.M., McNeill J.H. Adriamycin cardiomyopathy: pathological and membrane functional changes in a canine model with mild impairment of left ventricular function. Can. J. Cardiol. 1986, 2:368-374.
77. Trachtenberg B.H., Landy D.C., Franco V.I., Henkel J.M., Pearson E.J., Miller T.L., Lipshultz S.E. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr. Cardiol. 2011, 32:342-353.
78. Urbanova D., Urban L., Simkova I., Danova K., Mikuskova E., Mladosievicova B. Long-term cardiac effects of treatment for childhood leukemia. Neoplasma 2010, 57:179-183.
79. Van Asperen J., Van Tellingen O., Tijssen F., Schinkel A.H., Beijnen J.H. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer 1999, 79:108-113.
80. Van Vleet J.F., Ferrans V.J. Clinical and pathologic features of chronic adriamycin toxicosis in rabbits. Am. J. Vet. Res. 1980, 41:1462-1469.
81. Van Vleet J.F., Greenwood L.A., Ferrans V.J. Pathologic features of adriamycin toxicosis in young pigs: Nonskeletal lesions. Am. J. Vet. Res. 1979, 40:1537-1552.
82. Vici P., Colucci G., Giotta F., Sergi D., Filippelli G., Perri P., Botti C., Vizza E., Carpino A., Pizzuti L., Latorre A., Giannarelli D., Lopez M., Di Lauro L. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J. Exp. Clin. Cancer Res. 2011, 30:39.
83. Von Hoff D.D., Layard M.W., Basa P., Davis H.L., Von Hoff A.L., Rozencweig M., Muggia F.M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979, 91:710-717.
84. Wallace K.B., Hausner E., Herman E., Holt G.D., MacGregor J.T., Metz A.L., Murphy E., Rosenblum I.Y., Sistare F.D., York M.J. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol. Pathol. 2004, 32:106-121.
85. Wilson A.G. Short Term, Subchronic and Chronic Toxicology Studies. Principles and Methods of Toxicology 2001, 917-958. Taylor and Francis, Philadelphia, PA. 4th ed. W. Hayes (Ed.).
86. Wouters K.A., Kremer L.C.M., Miller T.L., Herman E.H., Lipshultz S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 2005, 131:561-578.
87. Wu A.H.B., Feng Y.J. Biochemical differences between cTnT and cTnI and their significance for diagnosis of acute coronary syndromes. Eur. Heart J. 1998, 19:N25-N29.
88. Xin Y.F., You Z.Q., Gao H.Y., Zhou G.L., Chen Y.X., Yu J., Xuan Y.X. Protective effect of lycium barbarum polysaccharides against doxorubicin-induced testicular toxicity in rats. Phytother. Res. 2012, 26:716-721.
89. Yamaguchi K., Fujisawa M. Anticancer chemotherapeutic agents and testicular dysfunction. Reprod. Med. Biol. 2011, 10:81-87.
90. Yeager A.M., Levin J., Levin F.C. The effects of 5-fluorouracil on hematopoiesis: studies of murine megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels. Exp. Hematol. 1983, 11:944-952.
91. Young D.M. Pathologic effects of adriamycin (NSC 123127) in experimental systems. Cancer Chemother. Rep. 1975, 6:159-175.
92. Zhao X., Zhang J., Tong N., Liao X., Wang E., Li Z., Luo Y., Zuo H. Berberine attenuates doxorubicin-induced cardiotoxicity in mice. J. Int. Med. Res. 2011, 39:1720-1727.
93. Zhou S., Palmeira C.M., Wallace K.B. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol. Lett. 2001, 121:151-157.
94. Zuckerman K.S., Sullivan R., Quesenberry P.J. Effects of actinomycin D in vivo on murine erythroid stem cells. Blood 1978, 51:957-969.